Metabolic dysfunction-associated steatohepatitis (MASH), the progressive form of MASLD characterized by inflammation and hepatocyte injury, is expected to overtake chronic hepatitis C as the most common indication for liver transplantation (Goldberg et al., 2017
Diabetes, Obesity and Metabolism , 24(8), 15531564
It means your body has adapted
Final Verdict: Research Comparison Feature Tirzepatide Retatrutide Receptor Targets GLP-1, GIP GLP-1, GIP, Glucagon Half-Life ~5 Days ~6 Days Max Published Weight Loss ~21% (72w) ~24% (48w) Liver Fat Reduction Moderate/High Extreme Primary Research Focus Glycemic Control Metabolic Reset / REE Future Outlook: Post-2025 Research Landscape As we look toward 2026 and beyond, the data from the Phase 3 TRIUMPH trials will likely solidify retatrutides position in the metabolic research hierarchy
Low energy, brain fog, and mood swings often stem from an overlooked cause: a vitamin B12 deficiency